Neuphoria Therapeutics Inc. Common Stock

Neuphoria Therapeutics reported achieving last patient last visit milestone in AFFIRM-1 Phase 3 trial for BNC-210 in social anxiety disorder, with topline data expected in early Q4 2025. The company extended its cash runway through fiscal Q2 2027 and reported a reduced net loss compared to the previous year.